Porphyria
Reading File
Finding Sources
Porphyria is a broad topic covering multiple distinct disorders. Based on the medical library (Harrison's Internal Medicine, Fitzpatrick's Dermatology, Andrews' Diseases of the Skin, Emery's Medical Genetics, and others), here's the landscape:
Overview
Porphyrias are a group of inherited (mostly autosomal dominant, some recessive) metabolic disorders caused by enzyme defects in the heme biosynthesis pathway. Each defect causes accumulation of specific heme precursors (porphyrins or their precursors ALA and PBG), producing distinct clinical patterns. They are broadly split into:
- Acute (neurovisceral) porphyrias - e.g., Acute Intermittent Porphyria (AIP), Variegate Porphyria (VP), Hereditary Coproporphyria (HCP), ALA-dehydratase deficiency porphyria - present with abdominal pain, neuropathy, psychiatric symptoms, often triggered by drugs, fasting, alcohol, hormonal changes.
- Cutaneous porphyrias - e.g., Porphyria Cutanea Tarda (PCT, most common), Erythropoietic Protoporphyria (EPP), Congenital Erythropoietic Porphyria (CEP) - present with photosensitivity, blistering, skin fragility.
- Mixed - Variegate porphyria has both neurovisceral and cutaneous features.
Topic breakdown
- Heme biosynthesis pathway and enzyme defects (which enzyme = which porphyria)
- Acute Intermittent Porphyria (AIP) - presentation, triggers, diagnosis, management
- Porphyria Cutanea Tarda (PCT) - most common type, cutaneous findings, iron/HCV link
- Variegate Porphyria and Hereditary Coproporphyria
- Erythropoietic porphyrias (EPP, Congenital Erythropoietic Porphyria/Gunther disease)
- Diagnosis and lab workup (urine PBG/ALA, plasma/fecal porphyrins, genetic testing)
- Acute attack management (hemin, glucose, avoiding triggering drugs) and long-term/genetic counseling
- Drugs and precipitating factors to avoid
Which of these would you like me to go into detail on, or would you like a general overview covering all of them?
Asking for Preferences
Which aspect of porphyria would you like to explore in depth?
Porphyria is a broad topic covering multiple distinct disorders. Based on the medical library (Harrison's Internal Medicine, Fitzpatrick's Dermatology, Andrews' Diseases of the Skin, Emery's Medical Genetics, and others), here's the landscape:
Overview
Porphyrias are a group of inherited (mostly autosomal dominant, some recessive) metabolic disorders caused by enzyme defects in the heme biosynthesis pathway. Each defect causes accumulation of specific heme precursors (porphyrins or their precursors ALA and PBG), producing distinct clinical patterns. They are broadly split into:
- Acute (neurovisceral) porphyrias - e.g., Acute Intermittent Porphyria (AIP), Variegate Porphyria (VP), Hereditary Coproporphyria (HCP), ALA-dehydratase deficiency porphyria - present with abdominal pain, neuropathy, psychiatric symptoms, often triggered by drugs, fasting, alcohol, hormonal changes.
- Cutaneous porphyrias - e.g., Porphyria Cutanea Tarda (PCT, most common), Erythropoietic Protoporphyria (EPP), Congenital Erythropoietic Porphyria (CEP) - present with photosensitivity, blistering, skin fragility.
- Mixed - Variegate porphyria has both neurovisceral and cutaneous features.
Topic breakdown
- Heme biosynthesis pathway and enzyme defects (which enzyme = which porphyria)
- Acute Intermittent Porphyria (AIP) - presentation, triggers, diagnosis, management
- Porphyria Cutanea Tarda (PCT) - most common type, cutaneous findings, iron/HCV link
- Variegate Porphyria and Hereditary Coproporphyria
- Erythropoietic porphyrias (EPP, Congenital Erythropoietic Porphyria/Gunther disease)
- Diagnosis and lab workup (urine PBG/ALA, plasma/fecal porphyrins, genetic testing)
- Acute attack management (hemin, glucose, avoiding triggering drugs) and long-term/genetic counseling
- Drugs and precipitating factors to avoid
Which of these would you like me to go into detail on, or would you like a general overview covering all of them?
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching Images
heme biosynthesis pathway enzyme defects porphyria diagram
Searching Images
porphyria cutanea tarda skin blisters dorsum of hand
This clinical photograph displays a side-by-side comparison of the dorsal and palmar surfaces of a human hand, illustrating a bullous dermatosis. The left image (dorsal view) shows significant pathology characterized by multiple, large, tense bullae of varying sizes localized to the dorsum of the hand and fingers. Several bullae have ruptured, revealing raw, erythematous bases with overlying crusting and superficial erosions. The surrounding skin exhibits hyperpigmentation and signs of chronic inflammation or scarring. In contrast, the right image (palmar view) demonstrates a relative sparing of the palmar surface, which remains largely intact without visible blisters or erosions. This distribution—blisters on sun-exposed dorsal areas with palmar sparing—is a hallmark of porphyria cutanea tarda (PCT) or pseudoporphyria, often seen in the context of chronic kidney disease and hemodialysis. The clinical significance lies in demonstrating the photosensitive nature of these skin lesions and the typical morphological findings of fluid-filled vesicles and bullae on fragile, sun-exposed skin.
Clinical photograph showing the dorsum of a hand in a patient with darker skin (Fitzpatrick type IV-VI), demonstrating classic manifestations of Porphyria Cutanea Tarda (PCT). The image shows a polymorphic eruption characterized by multiple tense bullae (blisters), some of which have ruptured to form raw, red erosions. Chronic changes are prominent, including mottled pigmentary alterations with areas of hyperpigmentation and vitiligo-like hypopigmentation (depigmentation). Shallow, atrophic scars and evidence of skin fragility are visible across the metacarpal area and phalanges. The skin texture appears thickened with exaggerated markings (lichenification), consistent with chronic photo-induced damage. These findings illustrate the hallmark features of PCT, where porphyrin-mediated phototoxicity leads to extreme mechanical fragility and blistering in sun-exposed areas. This visual is highly relevant for medical education regarding metabolic photodermatoses and their differential diagnosis from chronic actinic dermatitis or pellagra.
Searching PubMed
porphyria treatment
Porphyria
Porphyrias are a group of mostly inherited metabolic disorders caused by partial deficiencies of specific enzymes in the heme biosynthetic pathway. Each block causes a build-up of a distinct set of precursors (ALA, porphobilinogen (PBG), or various porphyrins), which produces a characteristic clinical picture (Biochemistry, 8th ed - Lippincott Illustrated Reviews; Thompson & Thompson Genetics and Genomics in Medicine, 9th ed).
Classification
| Category | Types | Mechanism of symptoms |
|---|---|---|
| Acute (neurovisceral) hepatic porphyrias | Acute Intermittent Porphyria (AIP), Variegate Porphyria (VP), Hereditary Coproporphyria (HCP), ALA-dehydratase deficiency porphyria | Neurotoxic accumulation of ALA/PBG |
| Cutaneous porphyrias | Porphyria Cutanea Tarda (PCT), Congenital Erythropoietic Porphyria (CEP), Erythropoietic Protoporphyria (EPP) | Phototoxic porphyrins deposited in skin, activated by UV light |
| Mixed | Variegate porphyria, Hereditary coproporphyria | Both neurovisceral attacks and photosensitive skin lesions |
Enzyme-defect map (Biochemistry, 8th ed - Lippincott Illustrated Reviews):
- ALA dehydratase deficiency -> ALA dehydratase deficiency porphyria
- PBG deaminase (HMB synthase) deficiency -> Acute Intermittent Porphyria
- Uroporphyrinogen III synthase deficiency -> Congenital Erythropoietic Porphyria
- Uroporphyrinogen decarboxylase (UROD) deficiency -> Porphyria Cutanea Tarda
- Coproporphyrinogen oxidase deficiency -> Hereditary Coproporphyria
- Protoporphyrinogen oxidase deficiency -> Variegate Porphyria
- Ferrochelatase deficiency -> Erythropoietic Protoporphyria
Most are autosomal dominant with low penetrance (only ~10-20% of gene carriers become symptomatic); CEP and ALA-dehydratase deficiency porphyria are autosomal recessive. "Dual porphyria" occurs when a patient carries defects in two pathway enzymes, most often UROD plus one other (Tietz Textbook of Laboratory Medicine, 7th ed).
Acute Intermittent Porphyria (most relevant acute type)
AIP is the most common acute porphyria and is due to ~50% reduction in PBG deaminase activity. Attacks are precipitated by drugs (barbiturates, sulfonamides, many anticonvulsants, alcohol), fasting/caloric restriction, infection, and hormonal changes (attacks are more common in women, often perimenstrual). Clinical features:
- Severe abdominal pain (up to 95%), nausea/vomiting, constipation (Andrews' Diseases of the Skin)
- Motor neuropathy/paresis (50-70%), seizures
- Neuropsychiatric disturbance (anxiety, hallucinations, confusion)
- Hyponatremia, hypertension, tachycardia
- No skin lesions (distinguishing it from VP and HCP)
- Urine PBG and ALA markedly elevated, urine darkens on standing (Yamada's Textbook of Gastroenterology, 7th ed; Henry's Clinical Diagnosis and Management by Laboratory Methods)
Porphyria Cutanea Tarda (most common overall)
PCT results from acquired or inherited deficiency of UROD and is strongly associated with hepatic iron overload, alcohol use, hepatitis C, estrogen use, and hemochromatosis (Harrison's Principles of Internal Medicine, 22nd ed). It presents with:
- Photosensitivity, skin fragility, tense blisters on sun-exposed, trauma-prone areas (dorsal hands)
- Hypertrichosis, hyperpigmentation, sclerodermoid skin changes
- No acute neurovisceral attacks and normal urine PBG (helps distinguish from acute porphyrias)
Other cutaneous porphyrias
- Congenital Erythropoietic Porphyria (Gunther disease) - severe, presents in infancy with mutilating photosensitivity, hemolytic anemia, and erythrodontia
- Erythropoietic Protoporphyria - childhood onset of acute painful burning photosensitivity (not primarily blistering), due to ferrochelatase deficiency
Diagnosis
- Acute attack: spot urine PBG and ALA (markedly elevated in AIP, VP, HCP)
- Cutaneous disease: plasma and fecal porphyrin fractionation to distinguish PCT, VP, HCP, EPP
- Enzyme assays and genetic testing confirm the specific type and allow family screening
- During latency, biochemical markers can be normal, so genetic testing matters for at-risk relatives
Management
Acute attacks (Harrison's, GOLDMAN-CECIL Medicine, Dermatology 2-Volume Set 5e):
- IV hemin (heme arginate/hematin) is first-line - suppresses hepatic ALA synthase and reduces precursor overproduction
- IV glucose/carbohydrate loading (≥300 g/day) is a temporizing measure only if hemin is unavailable or the attack is mild
- Symptom control: analgesia, antiemetics, careful fluid/electrolyte monitoring (watch for hyponatremia)
- Avoid all porphyrinogenic drugs (checked against a porphyria drug safety database)
- Givosiran, an RNAi therapeutic that silences hepatic ALA synthase-1, was approved (FDA 2019, EMA 2020) for recurrent attacks in acute hepatic porphyria - a major recent addition beyond hemin
PCT: therapeutic phlebotomy to reduce hepatic iron, low-dose hydroxychloroquine/chloroquine, avoidance of alcohol/estrogens, and treating underlying hepatitis C.
Long-term: genetic counseling, trigger avoidance, and for recurrent severe attacks, givosiran or liver transplantation in refractory cases.
Recent evidence note
A 2024 meta-analysis (PMID: 39438413) found that patients with acute hepatic porphyrias, particularly AIP, carry a significantly increased long-term risk of hepatocellular carcinoma, supporting periodic liver imaging surveillance in older patients with longstanding disease - this is a more recent finding worth flagging alongside the standard textbook management above.
If you want, I can go deeper into any single type (e.g., a full workup algorithm for a suspected acute attack, or the genetics/inheritance patterns in more detail).
This is a shared conversation. Sign in to Orris to start your own chat.